Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats

Pharmacology Biochemistry and Behavior

Volumn 112, Issue , 2013, Pages 29-33

  Wilmouth, Carrie E ^a   Zheng, Guangrong ^b   Crooks, Peter A ^b   Dwoskin, Linda P ^b   Bardo, Michael T ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

Author keywords

Dopamine; Methamphetamine; Self administration; VMAT2

Indexed keywords

GZ 793A; METHAMPHETAMINE; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FOOD INTAKE; HABITUATION; INSTRUMENTAL CONDITIONING; MALE; METHAMPHETAMINE DEPENDENCE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT;

RATTUS;

DOPAMINE; METHAMPHETAMINE; SELF-ADMINISTRATION; VMAT2;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; LOBELINE; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84885337728     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.09.006     Document Type: Article

References (29)

1. T.E. Albertson, R.W. Derlet, and B.E. Van Hoozen Methamphetamine and the expanding complications of amphetamines West J Med 170 1999 214 219 (Pubitemid 32612757)
2. A.M. Barr, W.J. Panenka, G.W. MacEwan, A.E. Thornton, D.J. Lang, and W.G. Honer The need for speed: an update on methamphetamine addiction J Psychiatry Neurosci 31 2006 301 313 (Pubitemid 44497427)
3. J.S. Beckmann, E.D. Denehy, G. Zheng, P.A. Crooks, L.P. Dwoskin, and M.T. Bardo The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats Psychopharmacology (Berl) 220 2012 395 403
4. S. Darke, S. Kaye, R. McKetin, and J. Duflou Major physical and psychological harms of methamphetamine use Drug Alcohol Rev 27 2008 253 262
5. P.B. Dews Studies on behavior. IV. Stimulant actions of methamphetamine J Pharmacol Exp Ther 122 1958 137 147
6. L.P. Dwoskin, and P.A. Crooks A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse Biochem Pharmacol 63 2002 89 98 (Pubitemid 34158807)
7. T.S. Guillot, and G.W. Miller Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons Mol Neurobiol 39 2009 149 170
8. S.B. Harrod, L.P. Dwoskin, P.A. Crooks, J.E. Klebaur, and M.T. Bardo Lobeline attenuates d-methamphetamine self-administration in rats J Pharmacol Exp Ther 298 2001 172 179 (Pubitemid 32574524)
9. B.D. Homer, T.M. Solomon, R.W. Moeller, A. Mascia, L. DeRaleau, and P.N. Halkitis Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications Psychol Bull 134 2008 301 310
10. D.B. Horton, K.B. Siripurapu, G. Zheng, P.A. Crooks, and L.P. Dwoskin Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release J Pharmacol Exp Ther 339 2011 286 297
11. R.T. Kelleher, and W.H. Morse Determinants of the specificity of behavioral effects of drugs Ergeb Physiol 60 1968 1 56
12. N. Kitanaka, J. Kitanaka, and M. Takemura Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration Eur J Pharmacol 474 2003 63 70 (Pubitemid 37289146)
13. F.J. Kogan, W.K. Nichols, and J.W. Gibb Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels Eur J Pharmacol 36 1976 363 371
14. K.E. Larsen, E.A. Fon, T.G. Hastings, R.H. Edwards, and D. Sulzer Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis J Neurosci 22 2002 8951 8960 (Pubitemid 35379065)
15. J. Lynch, and M.A. House Cardiovascular effects of methamphetamine J Cardiovasc Nurs 6 1992 12 18
16. M.N. Martinez, and G.L. Amidon A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals J Clin Pharmacol 42 2002 620 643 (Pubitemid 34547446)
17. J.C. Maxwell, and B.A. Rutkowski The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007 Drug Alcohol Rev 27 2008 229 235
18. R. McKetin, N. Kozel, J. Douglas, R. Ali, B. Vicknasingam, and J. Lund The rise of methamphetamine in Southeast and East Asia Drug Alcohol Rev 27 2008 220 228
19. D.K. Miller, P.A. Crooks, L. Teng, J.M. Witkin, P. Munzar, and S.R. Goldberg Lobeline inhibits the neurochemical and behavioral effects of amphetamine J Pharmacol Exp Ther 296 2001 1023 1034 (Pubitemid 32187378)
20. D.K. Miller, P.A. Crooks, G. Zheng, V.P. Grinevich, S.D. Norrholm, and L.P. Dwoskin Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters J Pharmacol Exp Ther 310 2004 1035 1045 (Pubitemid 39108925)
21. J.B. Murray Psychophysiological aspects of amphetamine-methamphetamine abuse J Psychol 132 1998 227 237 (Pubitemid 128469739)
22. N.M. Neugebauer, S.B. Harrod, D.J. Stairs, P.A. Crooks, L.P. Dwoskin, and M.T. Bardo Lobelane decreases methamphetamine self-administration in rats Eur J Pharmacol 571 2007 33 38 (Pubitemid 47284051)
23. J.R. Nickell, S. Krishnamurthy, S. Norrholm, G. Deaciuc, K.B. Siripurapu, and G. Zheng Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2 J Pharmacol Exp Ther 332 2010 612 621
24. V.V. Ranade Drug delivery systems 5A. Oral drug delivery J Clin Pharmacol 31 1991 2 16
25. J.C. Scott, S.P. Woods, G.E. Matt, R.A. Meyer, R.K. Heaton, and J.H. Atkinson Neurocognitive effects of methamphetamine: a critical review and meta-analysis Neuropsychol Rev 17 2007 275 297 (Pubitemid 47498174)
26. A. Shahiwala Formulation approaches in enhancement of patient compliance to oral drug therapy Expert Opin Drug Deliv 8 2011 1521 1529
27. 3H] dopamine uptake J Pharmacol Exp Ther 280 1997 1432 1444 (Pubitemid 27166742)
28. R.A. Wise, and P.P. Rompre Brain dopamine and reward Annu Rev Psychol 40 1989 191 225
29. G. Zheng, L.P. Dwoskin, and P.A. Crooks Vesicular monoamine transporter 2: role as a novel target for drug development AAPS J 8 2006 E682 E692